DE/EN
  • Deutsch
  • English
  • About us
    • His­tory
    • Who we are
    • Man­age­ment
    • Found­a­tion
    • Super­vis­ory Board
    • Sci­entific Advis­ory Board
    • Sci­entific Advisors
  • Back­ground
  • Research
    • Dis­eases
    • Pro­jects
      • Uni­S­ens
    • Tech­no­lo­gies
    • Pub­lic­a­tions
  • Ser­vices
    • Gen­ome Editing
    • Human iPS cells
    • Meas­ure­ments to accom­pany (pre-)clinical studies
    • Reg­u­lat­ory services
  • Co-Oper­­a­­tions
  • News
  • Jobs
  • Con­tact
REPROGRAM - REFINE - REGENERATE REPROGRAM - REFINE - REGENERATE REPROGRAM - REFINE - REGENERATE REPROGRAM - REFINE - REGENERATE
  • About us
    • His­tory
    • Who we are
    • Man­age­ment
    • Found­a­tion
    • Super­vis­ory Board
    • Sci­entific Advis­ory Board
    • Sci­entific Advisors
  • Back­ground
  • Research
    • Dis­eases
    • Pro­jects
      • Uni­S­ens
    • Tech­no­lo­gies
    • Pub­lic­a­tions
  • Ser­vices
    • Gen­ome Editing
    • Human iPS cells
    • Meas­ure­ments to accom­pany (pre-)clinical studies
    • Reg­u­lat­ory services
  • Co-Oper­­a­­tions
  • News
  • Jobs
  • Con­tact

Archives

Monthly Archive for: "February, 2024"
Home » Archives for February 2024
Reg­u­lat­ory author­ity gives green light for fur­ther devel­op­ment of an Alzheimer’s antibody
 0
By p564569
In News, Start
Posted 19. February 2024

Reg­u­lat­ory author­ity gives green light for fur­ther devel­op­ment of an Alzheimer’s antibody

The Bavarian research company ISAR Bioscience is well on the way to a new Alzheimer's therapy.

READ MORE
  • +49 89 356 475 400
  • info@isarbioscience.de
NAV­IG­A­TION
  • About us
  • Back­ground
  • Research
  • Ser­vices
  • Co-Oper­­a­­tions
  • News
  • Jobs
  • Con­tact
© 2022 ISAR Bioscience. All rights reserved.
  • Cookie Set­tings
  • Pri­vacy Policy
  • Legal Inform­a­tion
  • Deutsch
back BACK